Sep 2026· Cell Communication and Signaling· 0 citations
TL;DR
The SUZ12P/RB1/E2F1/E2F1 axis is a novel prognostic biomarker and promising therapeutic target for NSCLC.
Abstract
Genome-wide studies have identified thousands of pseudogenes in the human genome, many of which are now recognized as functional regulators rather than inert genomic relics. Increasing evidence indicates that pseudogene-derived transcripts play critical roles in cancer; however, the role and mechanism of pseudogene-derived transcripts in non–small cell lung cancer (NSCLC) remain largely unclear.
We analyzed NSCLC transcriptome datasets to screen dysregulated pseudogenes. We verified SUZ12P expression in clinical samples and evaluated its prognostic value. Gain- and loss-of-function assays were performed to assess SUZ12P effects on NSCLC cell proliferation, migration, invasion, xenograft growth and lung metastasis in vitro and in vivo. RNA pull-down, mass spectrometry, RIP, co-IP and ChIP were used to explore molecular interactions. Palbociclib was applied to test therapeutic potential of the SUZ12P/RB1 axis.
SUZ12P was significantly upregulated in NSCLC and correlated with distant metastasis and poor overall survival. SUZ12P promoted NSCLC tumor growth and metastasis in vitro and in vivo. Mechanistically, SUZ12P directly bound the RBC domain of RB1, blocked PP1c–RB1 interaction, enhanced RB1 phosphorylation at Ser795/Ser807, and released E2F1. Activated E2F1 transcriptionally upregulated SUZ12 by binding its promoter, forming a SUZ12P/RB1/E2F1/SUZ12 regulatory axis. CDK4/6 inhibitor palbociclib disrupted this axis and reversed SUZ12P-driven oncogenic phenotypes.
Pseudogene transcript SUZ12P is an oncogenic driver in NSCLC that acts through the RB1–E2F1 pathway to activate SUZ12 transcription. The SUZ12P/RB1/E2F1 axis is a novel prognostic biomarker and promising therapeutic target for NSCLC.
It is suggested that UPK1A-AS1 is a hypoxia‐inducible oncogenic lncRNA that plays dual roles in cancer, with cancer type‐dependent associations with progression and immune modulation across malignancies and mechanistically mediating hypoxia‐associated drug resistance in HCC.
Ze-Kai Li, Min Luo, Shu-Sen Fang et al.· Analytical Cellular Patholog...· 0 citations
GAS5 suppresses HCC by modulating the miR-18a-5p-CADM2 axis and suggests that GAS5 and its downstream network may serve as potential therapeutic targets.
Shao-Ying Ke, Cong-Ren Wang, Shao-Ze Lin et al.· Biochemical Genetics· 0 citations
PPIB promotes prostate cancer progression and is associated with broad transcriptional and alternative splicing alterations, with enriched pathways involving DNA repair, the cell cycle, and amino acid metabolism.
Shuang-Yu Ma, Aikeshanjiang Ailiyaer, Hui-Xian Chen et al.· Frontiers in Oncology· 0 citations
The long noncoding RNA H19 has been widely attested as a promoter of breast cancer by favoring proliferation, migration, invasion, and tumor growth. In this study, we attempted to decipher molecular mechanisms underlying oncogenic activities of H19. Transcriptomic analyses revealed that H19 overexpression correlates wi...
Kekely Klouyovo, Evodie Peperstraete, Léa Mabille et al.· The FEBS Journal· 0 citations
Epithelial ovarian cancer (EOC) is a highly lethal malignant tumor, with a poor clinical prognosis due to its early peritoneal metastasis. However, the molecular mechanism driving this malignant spread has not been elucidated. In this study, by aggregating the post-transcriptional regulatory network mediated by long no...
Wen-Xiao Li, Xiao-Li Ma, Zhi-Hui Li et al.· Discover Oncology· 0 citations
To investigate the function of RBM39 in lung adenocarcinoma (LUAD), with a particular focus on its regulatory effect on the alternative splicing of NRG1-206 and its role in tumor progression. Differential expression analysis of RNA binding proteins (RBPs) in LUAD samples was performed using TCGA datasets. RBM39 exp...